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Background: Measurement of anti-malarial drug efficacy and resistance relies mainly on in vivo clinical trials,
in vitro/ex vivo assays and molecular markers detection. The existing in vitro/ex vivo assays, in particular those that
are using non-radioactive devices, need to be standardized and adapted to field conditions. SYBR Green assay offers
a rapid and cheap alternative to other in vitro assays, but it requires tools not commonly available in field laboratories.
Here is described a modified SYBR green I protocol to perform the parasite growth test with blood samples in endemic
areas, followed later by the SYBR green fluorescence assay performed at a specialized laboratory level.
Methods: In vitro susceptibility of Plasmodium falciparum clones HB3, 3D7, W2 and 7G8 to chloroquine (CQ),
dihydroartemisinin (DHA), pyronaridine (PYD) and piperaquine (PPQ) was tested. Fresh isolates of P. falciparum from
imported malaria cases were collected for ex vivo assays. The parasite suspension was added in 96-well plates predosed
with anti-malarial drugs and incubated for 72 hours at 37°C, 5% CO2. SYBR green I protocol was modified to dry the
plates after freeze-thawed process to mimic storage and shipping conditions. The plates were rehydrated with 200 μl
of complete RPMI medium for fluorescence assay.
Results: There were no significant differences in IC50 values of CQ, DHA, PYD and PPQ, determined by the modified
protocol, compared to standard protocol. Longer storage did not affect the IC50 values.
Conclusion: The SYBR green I modified protocol produced reliable results and could be a suitable method for
in vitro/ex vivo assays in field.
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Malaria kills many children annually and is endemic in
more than 100 countries [1,2]. The spread of resistant mal-
aria parasites to anti-malarial drugs, including artemisinin-
based combination therapy, is a major concern for malaria
control in endemic countries [3]. In the absence of effective
vaccine, chemotherapy remains one of the strategies to
control malaria. Continuous monitoring of current anti-
malarial drugs is needed to detect the spread of resistant
parasites strains and estimate the risk of therapeutic
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unless otherwise stated.Three main approaches including in vivo trials, in vitro/
ex vivo assays and molecular markers of drug resistance
are currently used to monitor anti-malarial drug efficacy
and drug resistance [4]. In vivo studies are considered the
gold standard for measuring the efficacy of anti-malarial
drugs [5]. They allow the measurement of clinical and
parasitological efficacy of anti-malarials drugs and the de-
tection of changes in treatment outcomes. Carrying out
in vivo efficacy trials requires time, qualified medical staff
and financial resources, which can represent a challenge
in resource-limited malaria-endemic countries. In addi-
tion, in vivo trials measure therapeutic efficacy rather than
drug resistance [6,7].
In vitro/ex vivo assays are indispensable means for
measuring the intrinsic susceptibility of malaria parasites
to anti-malarial drugs, and establishing baseline suscepti-
bility of local parasite isolates to newly introduced drugs.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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veloped for decades. These techniques include the WHO
microtest, the isotopic based tests, the enzyme-linked
immunosorbent assay (ELISA) and the SYBR green-based
tests [8,9]. However, the availability of these techniques is
limited in low-income countries due to financial cost, time
consumption and problems related to the management of
radioactive waste. The existing in vitro/ex vivo assays, in
particular those that are non-radioactive, need to be stan-
dardized [8]. SYBR Green I in vitro/ex vivo assay offers a
rapid, reproducible and cheap alternative to radioisotopic
methods [4,10,11]. This also requires specific material and
expertise commonly not available in field laboratories.
Here is the report of a modified SYBR green I protocol
to perform in vitro/ex vivo tests in two steps: doing
parasite culture on 96-well plate containing anti-malarial
drugs in standard conditions, and postponing the step of
SYBR green fluorescence assay for outsourcing with spe-
cialized laboratories. Such a standardized protocol for
conducting in vitro/ex vivo drug sensitivity assays for
field monitoring of drug-resistant malaria would allow
direct comparisons of in vitro/ex vivo results from differ-
ent laboratories involved in networks of anti-malarial




The following drugs were tested for ex vivo and in vitro
assay: chloroquine diphosphate salt (CQ, RMCQ20120605-
03 [20 mg]); dihydroartemisinin (DHA, RMDHA20120511-
04 [20 mg]); pyronaridine tetraphosphate (PYD, RMPD201
30114-01 [200 mg]) and piperaquine tetraphosphate tetra-
hydrate (PPQ, RMPQ20130114-01 [200 mg]). These drugs
were provided by the WorldWide Antimalarial Resistance
Network (WWARN). The stock solutions of CQ, DHA
and PPQ were prepared in sterile distilled water and DHA
in methanol. A two point five–fold serial dilution of stock
solutions was made to obtain seven different concentra-
tions. The final concentrations ranged from 6.55 nM to
1600 nM for CQ, 0.07 nM to 16 nM for DHA, 0.33 nM to
80 nM for PYD and 1.31 to 320 nM for PPQ (Table 1).
Drugs were distributed at 25 μl per well in 96-wells plates.
Each drug was distributed in triplicate in the plate. TheTable 1 The final concentrations of drugs in serial
dilutions for in vitro/ex vivo assay
Dilution (nM) of Drugs D1 D2 D3 D4 D5 D6 D7 D8
CQ 1600 640 256 102 41 16.4 6.55 0
DHA 16 6.4 2.56 1.02 0.41 0.16 0.07 0
PYD 80 32 12.8 5.12 2.05 0.82 0.33 0
PPQ 320 128 51.2 20.5 8.19 3.28 1.31 0
CQ = chloroquine; DHA = dihydroartemisinin; PPQ = piperaquine;
PYD = pyronaridine. nM = nanomolar. All drugs concentrations are in nM.plates for ex vivo tests were dried overnight at room
temperature in sterile conditions and sealed with an adhe-
sive plastic, then stored at +4°C until use.
SYBR green I in vitro/ex vivo modified protocol
In vitro assay
Two chloroquine-sensitive (HB3, 3D7) and two chloro-
quine-resistant (7G8, W2) clones of Plasmodium falcip-
arum were tested for in vitro susceptibility against
chloroquine, dihydroartemisinin, pyronaridine and pipera-
quine. 3D7 and W2 were provided by WWARN; HB3 and
7G8 were from The Malaria Research and Reference Re-
agent Resource Center (MR4). The clones were cultured
in complete RPMI 1640 medium, with 0.5% Albimax +
hypoxanthine and gentamicin. They were incubated at
37°C, 5%CO2, 5%O2, 90%N2. An aliquot of the culture
was diluted to reduce the parasitaemia to 0.5%, and the
haematocrit was adjusted to 1.5%. This suspension was
then added (175 μl per well) to microplates predosed
with 25 μl of drugs and incubated for 72 hours at 37°,
5%C02, 5%O2, 90%N2. After freeze-thawed process, the
test was performed according to the SYBR Green I
standard and modified protocols (Figure 1). For the
standard protocol, the test was performed as described
by Bacon et al. [10]. Briefly, after homogenization of the
medium, lysis buffer and SYBR Green I were added and
fluorescence was read with the fluorimeter Tristar2
(Multimode Reader LB 942 Bertold Technologies) at
485 nm wave length using Microwin 2000 software. The
standard protocol was then modified by drying the
plates at 50°C for 10 hours after freeze-thawed process
to evaporate the culture medium (Figure 1). To assess
the impact of storage period on the values of IC50, the
dried plates were stored at room temperature during 24
hours and nine days. The plates were then rehydrated
with 200 μl of complete RPMI 1640 medium and incu-
bated at room temperature for at least 1 hour. Lysis buf-
fer and SYBR Green I were added and fluorescence
were read with the fluorimeter Tristar2 (Multimode
Reader LB 942 Bertold Technologies) at 485 nm wave
length using Microwin 2000 software. One millilitre of
the suspension was frozen at -20°C as control for para-
site growth.
Ex vivo assay
Fresh isolates were collected from nine imported clinical
malaria cases with parasitaemia ≥ 0.5% at the Lyon teach-
ing hospital, France. Tests were done within 48 hours after
bleeding, without culture adaptation. Blood samples were
collected before any anti-malarial treatment, washed three
times in complete RPMI 1640 medium and adjusted to
1.5% haematocrit and 0.5% parasitaemia by adding fresh
red blood cells. 175 μl suspension was added per well to
the plates containing 25 μl of the anti-malarial drugs.
Figure 1 SYBR Green I modified protocol for ex vivo/in vitro assay.
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CO2 and O2 controlled atmosphere. After the incuba-
tion time, plates were frozen and thawed for red
blood cells lysis before SYBR Green I analysis. SYBR
Green I analysis was performed according to the standard
and modified protocols as already described above for
in vitro tests (Figure 1).
Statistical analysis
The results from the Tristar2 were given in fluorescence
units (FU). The concentration at which the drugs were
able to inhibit 50% of parasite growth (IC50) was calcu-
lated through non-linear regression software. IC50 values
were validated if there was sufficient growth of parasites
with the ratio of FU (FU at concentration 0/FU at max-
imum concentration) ≥ 2, and a sigmoid curve generated
by the software. IC50 means were compared using the
t-test (α = 0.05) and the Ficher-Snedecor F-test for
variances.Results
Overall, three in vitro tests were performed for each
clone. The IC50 means calculated respectively by stand-
ard and modified protocols are summarized in Table 2.
No significant differences were seen in IC50s generated
for in vitro tests between the standard and modified
protocols.
Ex vivo susceptibility of P. falciparum was tested for
nine samples from patients. The average culture success
rate was 61.5% (ranged from 55.5-66.6%). The IC50 were
calculated respectively by standard and modified pro-
tocols and the results are summarized in Table 3. No
significant differences were seen in IC50s generated for
ex vivo samples between the standard and modified
protocols.
Discussion
Among the different in vitro/ex vivo assay methods, the
use of fluorescent labeling of DNA with SYBR Green
Table 2 The means of CI50 of the SYBR green based in vitro anti-malarial drugs assay according to protocols
Clone/drugs Protocol standard New Protocol (test) P
Mean CI50 (nM) 95% CI Mean CI50 (nM) 95% CI
3D7
CQ 31.10 ± 6.02 24.28-37.91 32.43 ± 4.31 26.22-35.97 0.77
DHA 2.30 ± 0.68 1.53-3.06 1.93 ± 0.43 1.81-2.78 0.47
PYD 8.82 ± 1.17 7.49-10.14 8.89 ± 1.54 7.07-10.56 0.97
PPQ 26.33 ± 1.71 21.38-28.27 25.66 ± 6.82 15.61-34.4 0.88
W2
CQ 467.66 ± 51.18 409.74-525.57 500.66 ± 87.22 368.96-566.35 0.60
DHA 1.94 ± 1.03 0.77-3.10 1.81 ± 0.99 0.81-3.06 0.81
PYD 5.35 ± 1.27 3.90-6.79 4.33 ± 1.21 3.98-6.71 0.37
PPQ 19.50 ± 2.91 16.20-22.79 17.20 ± 3.14 15.94-23.05 0.40
HB3
CQ 37.92 ± 6.66 30.38-45.47 50.28 ± 16.77 31.30-69.26 0.33
DHA 2.10 ± 0.97 0.99-3.20 1.99 ± 0.41 1.53-2.46 0.87
PYD 11.78 ± 2.36 9.10-14.46 12.51 ± 3.40 8.65-16.36 0.70
PPQ 21.70 ± 1.76 19.70-23.70 18.51 ± 2.24 15.97-21.06 0.12
7G8
CQ 416.98 ± 92.57 311.82-521.33 420.55 ± 96.04 311.87-529.24 0.18
DHA 0.65 ± 0.17 0.45-0.85 0.73 ± 0.12 0.58-0.87 0.56
PYD 4.43 ± 1.39 2.84-6.01 5.05 ± 0.34 4.66-5.44 0.52
PPQ 17.82 ± 3.57 13.77-21.87 15.98 ± 1.22 14.59-17.38 0.47
CQ = Chloroquine; DHA = Dihydroartemisinin; PPQ = Piperaquine; PYD = Pyronaridine; SD = Standard deviation, nM = nanomolar.
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tritiated hypoxanthine or ELISA [4,10-12]. However, the
fluorescence determination requires material not com-
monly available in field laboratories. Postponing the step
of fluorescence determination allows the use of SYBR
Green I protocol in field laboratories with limited re-
sources. It also offers opportunity (i) to do simultan-
eously ex vivo and in vivo tests during field studies, (ii)
to standardize protocols for data collection during multi-
center clinical studies, (iii) to store data for future use,
(iv) and to share original data with collaborators. The
SYBR Green I modified protocol described in this study
enables to dry and store the plates, which will be
analysed later by well-equipped laboratories. NetworksTable 3 Ex vivo susceptibility of Plasmodium falciparum isolat
piperaquine (standard and modified protocols)
Culture success rate (n/N) Standard pro
IC50 mean (n
CQ 66.6% (6/9) 484.08 [176-79
DHA 66.6% (6/9) 1.67 [1.21-2.12
PYD 55.5% (5/9) 14.23 [2.83-25
PPQ 55.5% (5/9) 78.22 [36.56-1
CQ = Chloroquine; DHA = Dihydroartemisinin; PPQ = Piperaquine; PYD = Pyronaridindevoted to anti-malarial drugs resistance assay [13-17],
may use this modified protocol for multicentre clinical
studies, that could result in reduction of instrumental and
systematic bias and facilitate the compilation, analysis and
interpretation of data from different study sites. The risks
of environment pollution are scarce and the technique
does not require specific protection of manipulator since
the SYBR Green is not radioactive [8] while its toxic for
DNA, and will be added to the culture in the laboratories
where the fluorescence will be read.
The plates were dried at 50°C to minimize the risk of
contamination of the culture with bacteria or fungi (higher
temperatures could eliminate the risk of contamination,
but they could denature the DNA of the parasite). Thees to chloroquine, dihydroartemisinin, pyronaridine and
tocol Modified protocol P
M) [95% CI] IC50 mean (nM) [95% CI]
1] 730.66 [595-995] 0.35
] 1.44 [0.88-2] 0.55
.63] 16.85 [1.69-32] 0.79
19.87] 74 [24.61-123.38] 0.90
e, nM = nanomolar.
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in vitro, then with field fresh isolates ex vivo. Samples were
collected from nine imported malaria cases (six from
Cameroon and three from the Democratic Republic
of Congo). Four patients have declared the use of
chemoprophylaxis against malaria (with chloroquine or
chloroquine-proguanil) prior to admission. The average
of culture success rate (interpretable tests) of ex vivo
assays was 61.5%, slightly lower than this described by
Tinto el al. (85%) [18], probably due to the small sample
size of the study reported here.
There was no significant difference between the means
of IC50 determined by the standard and modified proto-
cols. The values of IC50 determined in vitro by the modi-
fied protocol were broadly similar to those calculated
using the standard protocol (p > 0.10). The duration of
storage did not affect the IC50 value (IC50 of CQ against
7G8 ranged from 676 nM in standard protocol to 502 nM
after 24 hours and 9 days of storage of dried plates in modi-
fied protocol). A slight but not significant decrease was ob-
served in IC50 values of dried plates. These findings suggest
that the dried plates can be stored at room conditions and
be sent without special transportation requirements
since biological material is stable and non-infectious.
The means of IC50 of chloroquine against sensitive
clones 3D7 (32.43 nM, 95% CI: 26.22-35.97) and HB3
(50.28 nM, 95% CI: 31.3-69.2) determined in vitro by the
modified SYBR Green I protocol are broadly similar to
those already described in vitro by Garbi et al. in
Senegal, Mali, Cameroon and Côte d’Ivoire [19] and
Issaka et al. in Niger [20]. For ex vivo assays, our IC50
values of CQ (484.08 and 730.66 nM) are also compar-
able to the maximum values described by Tinto et al.
(using the semiautomated microdilution technique) in
Burkina Faso (8.3-595.9 nM) [18]. The lowers values
(8.3 nM) obtained by Tinto et al. could be the fact that
resistant and sensitive strains are circulating simultan-
eously in populations, and the large sample size included
in this study.
The means of IC50 of the chloroquine were high in
ex vivo assays (484.08 and 730.66 nM respectively in
standard and modified protocols). Malaria cases were
imported from chloroquine-resistance areas. High re-
sistance rates of P. falciparum to chloroquine have been
described in Cameroon since 2000 [21], even though
recent studies have shown decreases in resistance due to
changes in malaria treatment policies in these areas [19].
Conclusion
Drying and storing the plates did not affect the means of
IC50 values in a modified SYBR Green I protocol to
assess anti-malarial drugs. The modified protocol allows
performing in vitro/ex vivo tests in two steps. By post-
poning the step that requires SYBR Green methodology,the tests could be done in field conditions and the dried
plates could be transported in ambient conditions. Field
staff involved in multicentre studies may use this proto-
col to standardize the collect and share of data. It offers
the possibility to do simultaneously clinical in vivo and
ex vivo/in vitro assays in field. More in vitro/ex vivo
studies with large sample size are necessary for the valid-
ation of this protocol.
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